Abcellera Biologics is trading 4.1% lower at $12.13 as rising crude oil prices and a 4.99% 10-year Treasury yield pressure equity valuations. - No fresh company-specific announcement explains the September 23 decline. - The latest company update, announced September 16, concerns a planned October 1 presentation of ABCL635 Phase 2 data.